Determining the Locations of Dust Sources in FeLoBAL Quasars

We conduct a spectroscopic search of quasars observed by the Sloan Digital Sky Survey (SDSS) with broad absorption line (BAL) troughs due to Mg II and troughs due to Fe II that simultaneously exhibit strong Balmer narrow emission lines (NELs). We find that in a redshift range of 0.4 less than or equal to z less than or equal to 0.9 approximately 23 of the 70 Mg II BALs and 4 of a subset of 15 Fe II BALs exhibit strong Balmer emission. We also find significant fractions of Mg II BALs (approximately 23%) and those Mg II BALs with Fe II troughs (approximately 27%) have strong continuum reddening, E(B - V) greater than or equal to 0.1. From measurements of the Balmer decrement in three objects, we find similarly significant reddening of the NEL region in three of the four objects; the NELs in the fourth object are not measurable. We also include one object in this study not taken from the SDSS sample that shows Fe II absorption and strong narrow emission, but due to measurement uncertainty and low continuum reddening the comparison is consistent but inconclusive. We find a trend in both the Mg II and Fe II BAL samples between the NEL reddening and continuum reddening. Because the narrow line reddening is consistent with the continuum reddening in every object in the two SDSS samples, it suggests that the reddening sources in these objects likely exist at larger radial distances than the narrow line regions from the central nucleus.Comment: 40 manuscript pages, accepted in ApJ (July

Calcitriol suppression of parathyroid hormone fails to improve skeletal properties in an animal model of chronic kidney disease

BACKGROUND: Chronic kidney disease (CKD) leads to complex metabolic changes and an increased risk of fracture. Currently, calcitriol is the standard of care as it effectively suppresses parathyroid hormone (PTH) levels in CKD patients. While calcitriol and its analogs improve BMD and reduce fractures in the general population, the extension of these benefits to patients with advanced kidney disease is unclear. Here, the impact of calcitriol on the skeleton was examined in the setting of reduction in PTH. METHODS: Male Cy/+ rats, a PKD-like CKD model, were treated with either vehicle or calcitriol for 5 weeks. Their normal littermates served as controls. Animals were assessed for changes in mineral metabolism and skeletal parameters (microCT, histology, whole bone mechanics and bone quality). RESULTS: PTH levels were significantly higher (12-fold) in animals with CKD compared to normal controls. CKD animals also exhibited negative changes in bone structural and mechanical properties. Calcitriol treatment resulted in a 60% suppression of PTH levels in animals with CKD. Despite these changes, it had no impact on bone volume (cortical or cancellous), bone turnover, osteoclast number or whole bone mechanical properties. CONCLUSIONS: These data indicate that while calcitriol effectively lowered PTH in rats with CKD, it did little to prevent the negative effects of secondary hyperparathyroidism on the skeleton

The Quasar Outflow Contribution to AGN Feedback: VLT Measurements of SDSS J0318-0600

We present high spectral resolution VLT observations of the BAL quasar SDSS J0318-0600. This high quality data set allows us to extract accurate ionic column densities and determine an electron number density of n_e=10^3.3 +/- 0.2 cm^-3 for the main outflow absorption component. The heavily reddened spectrum of SDSS J0318-0600 requires purely silicate dust with a reddening curve characteristic of predominately large grains, from which we estimate the bolometric luminosity. We carry out photoionization modeling to determine the total column density, ionization parameter and distance of the gas and find that the photionization models suggest abundances greater than solar. Due to the uncertainty in the location of the dust extinction, we arrive at two viable distances for the main ouflow component from the central source, 6 and 18 kpc, where we consider the 6 kpc location as somewhat more physically plausable. Assuming the canonical global covering of 20% for the outflow and a distance of 6 kpc, our analysis yields a mass flux of 120 M_sun yr^-1 and a kinetic luminosity that is ~0.1% of the bolometric luminosity of the object. Should the dust be part of the outflow, then these values are ~4x larger. The large mass flux and kinetic luminosity make this outflow a significant contributor to AGN feedback processes.Comment: Accepted for publication in ApJ, 57 pages, 14 figure

Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease

Patients with chronic kidney disease (CKD) have an increased risk of fracture. Raloxifene is a mild antiresorptive agent that reduces fracture risk in the general population. Here we assessed the impact of raloxifene on the skeletal properties of animals with progressive CKD. Male Cy/+ rats that develop autosomal dominant cystic kidney disease were treated with either vehicle or raloxifene for five weeks. They were assessed for changes in mineral metabolism and skeletal parameters (microCT, histology, whole-bone mechanics, and material properties). Their normal littermates served as controls. Animals with CKD had significantly higher parathyroid hormone levels compared with normal controls, as well as inferior structural and mechanical skeletal properties. Raloxifene treatment resulted in lower bone remodeling rates and higher cancellous bone volume in the rats with CKD. Although it had little effect on cortical bone geometry, it resulted in higher energy to fracture and modulus of toughness values than vehicle-treated rats with CKD, achieving levels equivalent to normal controls. Animals treated with raloxifene had superior tissue-level mechanical properties as assessed by nanoindentation, and higher collagen D-periodic spacing as assessed by atomic force microscopy. Thus, raloxifene can positively impact whole-bone mechanical properties in CKD through its impact on skeletal material properties

Fortifying or fragmenting the state? The political economy of the drug trade in Shan State, Myanmar, 1988-2012

Over the past twenty-five years, the government of Myanmar (Burma) has consolidated control over large parts of Shan State, neutralizing much of the threat posed by armed groups and strengthening its hold over revenue extraction. During this period Myanmar has retained its position as the world's second largest producer of illicit opium, much of which is converted into heroin within the country's borders. This article explores the relationship between state-building processes and the illicit opium/heroin economy in Shan State since 1988. The author has four aims. First, to reassess the theoretical assumptions that equate illicit economies with state fragility and demonstrate instead why illicit drug economies can become embedded in processes of conflict reduction and state consolidation. Second, to explain why establishing control over Shan State has become so important to the Myanmar government's state-building ambitions. Third, to analyze how the state's engagement with the drug trade has become a vital part of its attempts to consolidate control, in terms of financing military expansion and brokering deals with strongmen who are able to govern local populations. Finally, to assess how these strategies embody a form of “negotiated statehood” in which the state's growing control has been defined by attempts to manage, rather than monopolize, the means of coercion and extraction

Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study

Background: Surgical site infection (SSI) is one of the most common infections associated with health care, but its importance as a global health priority is not fully understood. We quantified the burden of SSI after gastrointestinal surgery in countries in all parts of the world. Methods: This international, prospective, multicentre cohort study included consecutive patients undergoing elective or emergency gastrointestinal resection within 2-week time periods at any health-care facility in any country. Countries with participating centres were stratified into high-income, middle-income, and low-income groups according to the UN's Human Development Index (HDI). Data variables from the GlobalSurg 1 study and other studies that have been found to affect the likelihood of SSI were entered into risk adjustment models. The primary outcome measure was the 30-day SSI incidence (defined by US Centers for Disease Control and Prevention criteria for superficial and deep incisional SSI). Relationships with explanatory variables were examined using Bayesian multilevel logistic regression models. This trial is registered with ClinicalTrials.gov, number NCT02662231. Findings: Between Jan 4, 2016, and July 31, 2016, 13 265 records were submitted for analysis. 12 539 patients from 343 hospitals in 66 countries were included. 7339 (58·5%) patient were from high-HDI countries (193 hospitals in 30 countries), 3918 (31·2%) patients were from middle-HDI countries (82 hospitals in 18 countries), and 1282 (10·2%) patients were from low-HDI countries (68 hospitals in 18 countries). In total, 1538 (12·3%) patients had SSI within 30 days of surgery. The incidence of SSI varied between countries with high (691 [9·4%] of 7339 patients), middle (549 [14·0%] of 3918 patients), and low (298 [23·2%] of 1282) HDI (p < 0·001). The highest SSI incidence in each HDI group was after dirty surgery (102 [17·8%] of 574 patients in high-HDI countries; 74 [31·4%] of 236 patients in middle-HDI countries; 72 [39·8%] of 181 patients in low-HDI countries). Following risk factor adjustment, patients in low-HDI countries were at greatest risk of SSI (adjusted odds ratio 1·60, 95% credible interval 1·05–2·37; p=0·030). 132 (21·6%) of 610 patients with an SSI and a microbiology culture result had an infection that was resistant to the prophylactic antibiotic used. Resistant infections were detected in 49 (16·6%) of 295 patients in high-HDI countries, in 37 (19·8%) of 187 patients in middle-HDI countries, and in 46 (35·9%) of 128 patients in low-HDI countries (p < 0·001). Interpretation: Countries with a low HDI carry a disproportionately greater burden of SSI than countries with a middle or high HDI and might have higher rates of antibiotic resistance. In view of WHO recommendations on SSI prevention that highlight the absence of high-quality interventional research, urgent, pragmatic, randomised trials based in LMICs are needed to assess measures aiming to reduce this preventable complication

Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing

Background Chronic kidney disease (CKD) results in a dramatic increase in skeletal fracture risk. Bisphosphates (BP) are an effective treatment for reducing fracture risk but they are not recommended in advanced CKD. We have recently shown higher acute skeletal accumulation of fluorescently-tagged zoledronate (ZOL) in the setting of CKD but how this accumulation is retained/lost over time is unclear. Furthermore, it is unknown if alternative dosing approaches can modulate accumulation in the setting of CKD. Methods To address these two questions normal (NL) and Cy/+ (CKD) rats were divided into control groups (no dosing), a single dose of a fluorescent-tagged ZOL (FAM-ZOL), a single dose of non-labelled zoledronate (ZOL) or ten weekly doses of FAM-ZOL each at 1/10th the dose of the single dose group. Half of the CKD animals in each group were provided water with 3% calcium in drinking water (CKD + Ca) to suppress PTH and remodeling. At 30 or 35 weeks of age, serum, tibia, ulna, radius, vertebra, femora, and mandible were collected and subjected to assessment methods including biochemistry, dynamic histomorphometry and multi-spectral fluorescence levels (using IVIS SpectrumCT). Results FAM-ZOL did not significantly reduce bone remodeling in either NL or CKD animals while Ca supplementation in CKD produced remodeling levels comparable to NL. At five- and ten-weeks post-dosing, both CKD and CKD + Ca groups had higher levels of FAM-ZOL in most, but not all, skeletal sites compared to NL with no difference between the two CKD groups suggesting that the rate of remodeling did not affect skeletal retention of FAM-ZOL. Fractionating the FAM-ZOL into ten weekly doses led to 20–32% less (p < 0.05) accumulation/retention of compound in the vertebra, radius, and ulna compared to administration as a single dose. Conclusions The rate of bone turnover does not have significant effects on levels of FAM-ZOL accumulation/retention in animals with CKD. A lower dose/more frequent administration paradigm results in lower levels of accumulation/retention over time. These data provide information that could better inform the use of bisphosphonates in the setting of CKD in order to combat the dramatic increase in fracture risk

Skeletal accumulation of fluorescently-tagged zoledronate is higher in animals with early stage chronic kidney disease

This work examines the skeletal accumulation of fluorescently-tagged zoledronate in an animal model of chronic kidney disease. The results show higher accumulation 24-hours post-dose in animals with lower kidney function due to greater amounts of binding at individual surfaces.NIH F30 DK115162; NIH T32 AR065971; NIH P30 DK 07931

Modelling, simulation, and optimisation of agrivoltaic systems: a comprehensive review

Agrivoltaic systems combine food production and solar energy conversion on the same land, offering a dual-use approach to address land use concerns in renewable energy development. One of the main research and market challenges for agrivoltaic systems is the ability to predict food and energy yields prior to installation. The photovoltaic modules reduce solar irradiation on the ground, altering the energy balance at the ground and crop levels, affecting thus evapotranspiration and photosynthesis. The photovoltaic modules also influence local rain distribution and wind patterns, creating a microclimate that impacts both crop production and photovoltaic efficiency. The need to evaluate these effects and their impact on crop growth before installation is underscored by the recent implementation of new standards, guidelines, and regulations governing agrivoltaic systems in various regions. This study provides a critical review of existing research with a focus on the modelling, simulation, and optimisation of agrivoltaic systems. It highlights recent advancements in simulating and optimising the design of agrivoltaic systems through integrated simulations of shading, microclimates, electrical performance, and agricultural productivity. This study highlights the critical role of optimised light distribution in enhancing both crop yields and electricity production within agrivoltaic systems. However, the diversity of modelling approaches from the PV and agricultural sectors, coupled with the absence of standardised benchmarks, complicates the selection of appropriate models for specific systems and conditions. Future research should prioritise the development of standardised benchmarks to enable consistent comparisons across models, facilitating a better understanding of trade-offs between computational efficiency, interpretability, and accuracy. Collaborative efforts, publicly available datasets, and benchmarking initiatives are essential for validating models across diverse agrivoltaic configurations and regions.Modelling, simulation, and optimisation of agrivoltaic systems: a comprehensive reviewpublishedVersio